Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER

Published:2016-10-17 Issue:1 Volume:140 Page:208-215
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Subbiah Ishwaria M.¹,Wheler Jennifer J.²,Hess Kenneth R.³,Hong David S.²,Naing Aung²,Fu Siqing²,Kurzrock Razelle⁴,Tsimberidou Apostolia M.²

Affiliation:

1. Division of Cancer Medicine; The University of Texas MD Anderson Cancer Center; Houston TX

2. Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program); The University of Texas MD Anderson Cancer Center; Houston TX

3. Department of Biostatistics; The University of Texas MD Anderson Cancer Center; Houston TX

4. Moores Cancer Center; University of California; San Diego CA

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference35 articles.

1. Howlader NNA Krapcho M Garshell J. SEER Cancer Statistics Review, 1975-2010, National Cancer Institute http://seercancergov/csr/1975_2010/

2. Underrepresentation of patients 65 years of age or older in cancer-treatment trials;Hutchins;N Engl J Med,1999

3. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials;Unger;J Clin Oncol,2006

4. Participation in cancer clinical trials: race-, sex-, and age-based disparities;Murthy;J Am Med Assoc,2004

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study;ESMO Open;2022-06

2. Phase I trials and therapeutic intent in the age of precision oncology: What is a patient's chance of response?;European Journal of Cancer;2020-11

3. First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern Oncotherapeutics;Scientific Reports;2020-05-13

4. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials;Journal of the National Comprehensive Cancer Network;2020-04

5. Better to be in The Placebo Arm for Trials of Neurological Therapies?;Cell Transplantation;2018-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3